Ashkenazi jewish origin protects against formation of antibodies to infliximab and therapy failure

Medicine (United States)

Volumn 94, Issue 18, 2015, Pages

  Ungar, Bella ^a,c   Haj Natour, Ola ^a,c   Kopylov, Uri ^a,c   Yavzori, Miri ^a,c   Fudim, Ella ^a,c   Picard, Orit ^a,c   Loebstein, Ronen ^a,c   Lahat, Adi ^a,c   Maor, Yaakov ^a,c   Avidan, Benjamin ^a,c   Lang, Alon ^a,c   Weiss, Batia ^b,c   Chowers, Yehuda ^d   Eliakim, Rami ^a,c   Ben Horin, Shomron ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b Edmond and Lily Safra Children's Hospital   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY TO INFLIXIMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANTIBODY PRODUCTION; ARTICLE; ASHKENAZI JEW; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; ETHNICITY; FEMALE; GENETIC PREDISPOSITION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; ADOLESCENT; AGED; BLOOD; ETHNOLOGY; EVALUATION STUDY; FOLLOW UP; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; JEW; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; JEWS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84959525762     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000673     Document Type: Article

References (36)

1. Hanauer SB, Feagan BG, Lichtenstein GR., et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541-1549.
2. Sands BE, Anderson FH, Bernstein CN., et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004; 350:876-885.
3. Rutgeerts P, Sandborn WJ, Feagan BG., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476.
4. Ungar B, Chowers Y, Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2013; 63:1258-1264.
5. Vande Casteele N, Gils A, Singh S., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013; 108:962-971.
6. Ordas I, Mould DR, Feagan BG., et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012; 91:635-646.
7. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factoralpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohns disease. Am J Gastroenterol. 2008; 103:944-948.
8. Baert F, Noman M, Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med. 2003; 348:601-608.
9. Hanauer SB, Wagner CL, Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease. Clin Gastroenterol Hepatol. 2004; 2:542-553.
10. Kamm M.A. Review article: biological drugs in Crohns disease. Aliment Pharmacol Ther. 2006; 24(Suppl 3):80-89.
11. Colombel JF, Feagan BG, Sandborn WJ., et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:349-358.
12. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohns disease. Aliment Pharmacol Ther. 2003; 17:1451-1457.
13. Parsi MA, Achkar JP, Richardson S., et al. Predictors of response to infliximab in patients with Crohns disease. Gastroenterology. 2002; 123:707-713.
14. Vermeire S, Louis E, Carbonez A., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohns disease. Am J Gastroenterol. 2002; 97:2357-2363.
15. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19:2118-2124.
16. Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013; 38:1188-1197.
17. Higgins PD, Schwartz M, Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005; 54:782-788.
18. Harvey RF, Bradshaw JM. A simple index of Crohns-disease activity. Lancet. 1980; 1:514.
19. Vermeire S, Schreiber S, Sandborn WJ., et al. Correlation between the Crohns disease activity and Harvey-Bradshaw indices in assessing Crohns disease severity. Clin Gastroenterol Hepatol. 2010; 8:357-363.
20. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohns disease. Aliment Pharmacol Ther. 2011; 33:987-995.
21. Ben-Horin S, Yavzori M, Katz L., et al. The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011; 60:41-48.
22. Kopylov U, Mazor Y, Yavzori M., et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. 2012; 18:1628-1633.
23. Colombel JF, Sandborn WJ, Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med. 2010; 362:1383-1395.
24. Ben-Horin S, Waterman M, Kopylov U., et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11:444-447.
25. Criswell LA1, Lum RF, Turner KN., et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004; 50:2750-2756.
26. Dubinsky MC1, Mei L, Friedman M., et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16:1357-1366.
27. Karban A, Itay M, Davidovich O., et al. Risk factors for perianal Crohns disease: the role of genotype, phenotype, and ethnicity. Am J Gastroenterol. 2007; 102:1702-1708.
28. Karban A, Waterman M, Panhuysen CI., et al. NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohns disease. Am J Gastroenterol. 2004; 99: 1134-1140.
29. Shaoul R, Karban A, Reif S., et al. Disease behavior in children with Crohns disease: the effect of disease duration, ethnicity, genotype, and phenotype. Dig Dis Sci. 2009; 54:142-150.
30. Koifman E, Karban A, Mazor Y., et al. Thiopurine effectiveness in patients with Crohns disease: a study of genetic and clinical predictive factors. Inflamm Bowel Dis. 2013; 19:1639-1644.
31. Reinisch W, Wang Y, Oddens BJ., et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohns disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012; 35:568-576.
32. Cornillie F, Hanauer SB, Diamond RH., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014.
33. Seow CH, Newman A, Irwin SP., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010; 59:49-54.
34. Alzafiri R, Holcroft CA, Malolepszy P., et al. Infliximab therapy for moderately severe Crohns disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol. 2011; 4:9-17.
35. Panaccione R, Ghosh S, Middleton S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146:392-400e3.
36. Feagan BG, McDonald JW, Panaccione R., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohns disease. Gastroenterology. 2014; 146:681-688e1.